Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients


  • Quillien Véronique
  • Lavenu Audrey
  • Ducray François
  • Meyronet David
  • Chinot Olivier
  • Fina Frédéric
  • Sanson Marc
  • Carpentier Catherine
  • Karayan-Tapon Lucie
  • Rivet Pierre
  • Entz-Werle Natacha
  • Legrain Michèle
  • Zalcman Emmanuèle Lechapt
  • Levallet Guenaelle
  • Escande Fabienne
  • Ramirez Carole
  • Chiforeanu Dan
  • Vauleon Elodie
  • Figarella-Branger Dominique


  • Pyrosequencing
  • CE-IVD kit
  • Glioblastoma
  • MGMT methylation

document type



BACKGROUND: Pyrosequencing is recognized as a strong technique to analyze the MGMT status of glioblastoma patients. The most commonly used assay, quantifies the methylation levels of CpGs 74 to 78. A more recent CE-marked In Vitro Diagnostic Medical Device (CE-IVD) assay, Therascreen, analyzes CpGs 76-79.METHODS: We performed a comparison of these two assays to evaluate the potential impact of this shift in analyzed CpGs. Therascreen analysis was centrally performed for 102 glioblastoma patients, who were part of a prospective multicenter trial.RESULTS: A strong correlation was observed for the mean values of the 4 or 5 analyzed CpGs, with lower values recorded using the Therascreen assay, especially for values greater than 20%. When considering a classification in 3 categories (> 12%: methylated; ⩽ 8%: unmethylated; 9-12%: grey zone), 93% of patients were identically classified between the two assays. Using a binary classification, 95% and 97% of patients were identically classified with cut-offs of 8% and 12%, respectively. A strong prognostic significance was observed for both assays: median overall survival were 15.9 months and 34.9 months for respectively unmethylated and methylated patients with either test. CONCLUSION: The results demonstrate that these assays may be used interchangeably.

more information